Mylan

FULPHILA

  1. Home
  2.  / 
  3. Q Code
  4.  / FULPHILA – Q5108

Manufacturer:

Mylan

Name:

FULPHILA

HCPCS Code Descriptor:

Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg

Category:

Q Code

HCPCS:

Q5108

NDC(s):

67457-0833-06

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic Status:

Single-Source

Route of Administration:

Subcutaneous

About:

FULPHILA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Mylan and administered via the Subcutaneous route of administration. The Q Code: Q5108 is aligned to the drug FULPHILA.

Fulphila (pegfilgrastim) is used to prevent patients from developing a deficiency of certain white blood cells by aiding in the production of these white blood cells. This medication is manufactured by Mylan Institutional and is a biosimilar to the drug Neulasta (J2506). Patient assistance programs for this medication can be found through the Viatris Patient Assistance program.

Access Pricing and More By Registering

HCPCS Added Date:

10/1/18

HCPCS Effective Date:

4/1/23

HCPCS Short Description:

Injection, fulphila

Billing and Coding Guide:

https://www.viatrisadvocate.com/-/media/viatrisadvocatecom/pdf/fulphila/peg-2019-0149-v3-fulphila-billing-and-coding-guide.pdf

Patient Assistance:

https://www.viatris.com/en-us/lm/united-states/patient-assistance-program

FULPHILA - Q5108